MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

MaxCyte, Inc.NASDAQ: MXCT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $1.05M fell 18.0% year over year, behind the +4.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 18.6% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.

Context

  • Depreciation & amortization amounted to 15.6% of revenue in FY2025, up 4.4 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -18.0% toward the trailing-twelve-month pace of +4.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.05M-18.6% QoQ
Last fiscal yearDec 2025
$5.14M+19.2% YoY
LTMMar 2026
$4.68M+4.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.0%——
1 year+19.2%——
3-year CAGR+24.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
5.14M USD
Year-over-year change
+19.2%
4-year CAGR
+37.9%

Depreciation & Amortization vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 depreciation & amortization of $4.68M is the 3rd largest of the 11 companies compared; the peer median is $2.67M.
  • Its year-over-year change of +4.5% is the 5th highest of 10, against a peer median of -0.3%.
  • Depreciation & amortization amounts to 14.5% of revenue for MXCT, versus a peer median of 13.4%.
MXCT Competitors Peer median
Depreciation & Amortization for MXCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NNOXNano-X Imaging Ltd.LTM Dec 2025$11.7M -0.3%+0.5%89.8%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$6.56M -25.2%-28.2%19.0%
MXCTMaxCyte, Inc.LTM Mar 2026$4.68M +4.5%+24.0%14.5%
LNSRLENSAR, Inc.LTM Mar 2026$4.56M +11.6%+9.7%7.9%
PREPrenetics Global LimitedLTM Mar 2026$3.97M —-20.6%3.5%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$3.65M +35.4%+111.4%589.8%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M +7.8%+29.0%91.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$1.61M +16.3%+19.7%54.5%
OWLTOwlet, Inc.LTM Mar 2026$627K -41.1%-39.6%0.6%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$589K -20.5%+16.3%1.3%
PROFProfound Medical Corp.LTM Mar 2026$499.37K -27.3%-29.2%2.6%
Peer median (excluding MXCT) $2.67M-0.3%+5.1%13.4%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Depreciation & Amortization1.42M2.7M4.57M4.32M5.14M
Deferred Income Tax00000
Stock-Based Compensation7.96M013.98M09.21M
Change in Working Capital(1.64M)(3.21M)3.82M(751K)(6.12M)
Accounts Receivables(1.71M)(6.69M)7.14M1.23M1.15M
Inventory(1.41M)(3.49M)(4.53M)1.36M575K
Accounts Payables2.09M(149.7K)3.25M(1.88M)(3.72M)
Other Working Capital(624.7K)7.12M(2.04M)(1.46M)(4.13M)
Other Non-Cash Items664.6K9.3M(6.13M)9.88M1.99M
Operating Cash Flow(10.68M)(14.78M)(21.69M)(27.61M)(34.41M)
Capital Expenditures(3.83M)(18.48M)(3.7M)(1.65M)(1.77M)
Acquisitions (Net)0000(1.77M)
Purchases of Investments(268.68M)(290.94M)(255.1M)(150.86M)(126.29M)
Sales of Investments77.5M284.6M313.77M159.44M155.76M
Other Investing Activities4.6K09K00
Investing Cash Flow(195.01M)(24.82M)54.98M6.93M25.94M
Debt Repayment(4.99M)0000
Common Stock Issued236.08M2.89M269K2.06M656K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.63M01.87M00
Financing Cash Flow234.72M2.89M2.14M2.06M656K
Effect of Forex Changes00000
Net Change in Cash29.03M(36.72M)35.44M(18.62M)(7.82M)
Free Cash Flow(14.51M)(33.26M)(25.39M)(29.26M)(36.18M)

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.